Gary Raskob to Heparin
This is a "connection" page, showing publications Gary Raskob has written about Heparin.
Connection Strength
1.693
-
Different effects of heparin in males and females. Clin Invest Med. 1998 Apr; 21(2):71-8.
Score: 0.147
-
The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis. 1998; 28 Suppl 3:8-16.
Score: 0.144
-
Thrombotic complications of antithrombotic therapy: a paradox with implications for clinical practice. Ann Intern Med. 1997 Nov 01; 127(9):839-41.
Score: 0.142
-
Aging and heparin-related bleeding. Arch Intern Med. 1996 Apr 22; 156(8):857-60.
Score: 0.128
-
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May; 3(5):e228-36.
Score: 0.127
-
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9.
Score: 0.079
-
Heparin therapy for venous thrombosis and pulmonary embolism. Blood Rev. 1988 Dec; 2(4):251-8.
Score: 0.077
-
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007 Sep 13; 357(11):1094-104.
Score: 0.071
-
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost. 2007 Jun; 5(6):1191-4.
Score: 0.069
-
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):401S-428S.
Score: 0.057
-
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003 Oct 30; 349(18):1695-702.
Score: 0.054
-
Long-term anticoagulant therapy prevents recurrent venous thromboembolism. J R Soc Med. 1982 Apr; 75(4):289.
Score: 0.048
-
Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med. 2000 Jan 24; 160(2):229-36.
Score: 0.042
-
Hirudin versus heparin and low-molecular-weight heparin: and the winner is... J Lab Clin Med. 1998 Sep; 132(3):171-4.
Score: 0.038
-
Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997 Dec 8-22; 157(22):2562-8.
Score: 0.036
-
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):289-94.
Score: 0.034
-
Low molecular weight heparin, heparin, and warfarin. Curr Opin Hematol. 1995 Sep; 2(5):372-9.
Score: 0.031
-
Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost. 1995 Jul; 74(1):189-96.
Score: 0.030
-
Anticoagulants and thrombolysis in the treatment of pulmonary embolism. Curr Opin Pulm Med. 1995 Jul; 1(4):291-7.
Score: 0.030
-
Treatment of venous thromboembolism. Curr Opin Hematol. 1994 Sep; 1(5):329-35.
Score: 0.029
-
Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med. 1994 May 09; 154(9):999-1004.
Score: 0.028
-
Hemorrhagic complications of anticoagulant treatment. Chest. 1992 Oct; 102(4 Suppl):352S-363S.
Score: 0.025
-
Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992 Aug; 152(8):1589-95.
Score: 0.025
-
Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992 Apr 09; 326(15):975-82.
Score: 0.024
-
Venous thromboembolic disease. Curr Opin Cardiol. 1991 Oct; 6(5):750-6.
Score: 0.023
-
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990 May 03; 322(18):1260-4.
Score: 0.021
-
Pharmacokinetics and dynamics of heparin in patients with proximal vein thrombosis. J Clin Pharmacol. 1989 Oct; 29(10):896-900.
Score: 0.020
-
Anticoagulant therapy for venous thromboembolism. Prog Hemost Thromb. 1989; 9:1-27.
Score: 0.019
-
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986 Oct 30; 315(18):1109-14.
Score: 0.017
-
Prophylaxis of venous thromboembolic disease following hip and knee surgery. J Bone Joint Surg Am. 1986 Jan; 68(1):146-50.
Score: 0.016
-
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):287S-310S.
Score: 0.014
-
A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. JAMA. 1984 Jul 13; 252(2):235-9.
Score: 0.014
-
Hemorrhagic complications of anticoagulant treatment. Chest. 2001 Jan; 119(1 Suppl):108S-121S.
Score: 0.011
-
Hemorrhagic complications of anticoagulant treatment. Chest. 1998 Nov; 114(5 Suppl):511S-523S.
Score: 0.010
-
A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993 Nov 04; 329(19):1370-6.
Score: 0.007
-
Prophylaxis of venous thromboembolism. An overview. Chest. 1986 May; 89(5 Suppl):374S-383S.
Score: 0.004
-
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982 Dec 30; 307(27):1676-81.
Score: 0.003